Why the study?
Comparative effectiveness data for vitamin K antagonists, direct thrombin inhibitors, and factor Xa inhibitors in everyday clinical practice were needed for patients with AF at risk of stroke.
Does oral anticoagulant therapy, specifically NOACs compared to VKAs or no treatment, improve mortality and stroke outcomes without increasing major bleeding in patients with atrial fibrillation at risk of stroke?
Observational (n=25,551)
Yes
Does oral anticoagulant therapy, specifically NOACs compared to VKAs or no treatment, improve mortality and stroke outcomes without increasing major bleeding in patients with atrial fibrillation at risk of stroke?
Answers are grounded in this paper and cite their sources.
In everyday clinical practice, NOACs provide significant mortality and safety benefits regarding major bleeding compared to VKAs in patients with atrial fibrillation, while offering comparable stroke prevention.
OBJECTIVES: This study evaluated the comparative effectiveness of vitamin K antagonists (VKAs), direct thrombin inhibitors (DTIs) and factor Xa inhibitors (FXaI) in patients with atrial fibrillation (AF) at risk of stroke in everyday practice. RESULTS: All-cause mortality, non-haemorrhagic stroke/systemic embolism (SE) and major bleeding over 2 years were compared in 25 551 patients, 7162 (28.0%) not treated with oral anticoagulant (OAC) and 18 389 (72.0%) treated with OAC (FXaI (41.8%), DTI (11.4%) and VKA (46.8%)). OAC treatment compared with no OAC treatment was associated with decreased risk of all-cause mortality (HR 0.82 (95% CI 0.74 to 0.91)) and non-haemorrhagic stroke/SE (HR 0.71 (95% CI 0.57 to 0.88)) but increased risk of major bleeding (HR 1.46 (95% CI 1.15 to 1.86)). Non-vitamin K antagonist oral anticoagulant (NOAC) use compared with no OAC treatment was associated with lower risks of all-cause mortality and non-haemorrhagic stroke/SE (HR 0.67 (95% CI 0.59 to 0.77)) and 0.65 (95% CI 0.50 to 0.86)) respectively, with no increase in major bleeding (HR 1.10 (95% CI 0.82 to 1.47)). NOAC use compared with VKA use was associated with lower risk of all-cause mortality and major bleeding (rates/100 patient-years 3.6 (95% CI 3.3 to 3.9) vs 4.8 (95% CI 4.5 to 5.2) and 1.0 (95% CI 0.9 to 1.1) vs 1.4 (95% CI 1.2 to 1.6); HR 0.79 (95% CI 0.70 to 0.89) and 0.77 (95% CI 0.61 to 0.98) respectively), with similar risk of non-haemorrhagic stroke/SE (rates/100 patient-years 0.8 (95% CI 0.7 to 0.9) versus 1.0 (95% CI 0.8 to 1.1); HR 0.96 (95% CI 0.73 to 1.25). CONCLUSION: Important benefits in terms of mortality and major bleeding were observed with NOAC versus VKA with no difference among NOAC subtypes. TRIAL REGISTRATION NUMBER: NCT01090362.
No takes yet. Share an insight, caveat, or question.
Camm et al. (2021) conducted an observational in atrial fibrillation (AF) at risk of stroke (n=25,551). Non-vitamin K antagonist oral anticoagulants (NOAC) vs. Vitamin K antagonists (VKA) or no oral anticoagulant was evaluated on All-cause mortality (HR 0.79, 95% CI 0.70 to 0.89).
Synapse has enriched 10 related papers. Consider them for comparative context: